Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 189

1.

Effect of testosterone supplementation with and without a dual 5α-reductase inhibitor on fat-free mass in men with suppressed testosterone production: a randomized controlled trial.

Bhasin S, Travison TG, Storer TW, Lakshman K, Kaushik M, Mazer NA, Ngyuen AH, Davda MN, Jara H, Aakil A, Anderson S, Knapp PE, Hanka S, Mohammed N, Daou P, Miciek R, Ulloor J, Zhang A, Brooks B, Orwoll K, Hede-Brierley L, Eder R, Elmi A, Bhasin G, Collins L, Singh R, Basaria S.

JAMA. 2012 Mar 7;307(9):931-9. doi: 10.1001/jama.2012.227.

PMID:
22396515
2.

The role of 5α-reductase inhibition in men receiving testosterone replacement therapy.

Gruntmanis U.

JAMA. 2012 Mar 7;307(9):968-70. doi: 10.1001/jama.2012.259. No abstract available.

PMID:
22396520
3.

Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy.

Page ST, Hirano L, Gilchriest J, Dighe M, Amory JK, Marck BT, Matsumoto AM.

J Urol. 2011 Jul;186(1):191-7. doi: 10.1016/j.juro.2011.03.026.

4.
5.

Testosterone with dutasteride, but not anastrazole, improves insulin sensitivity in young obese men: a randomized controlled trial.

Juang PS, Peng S, Allehmazedeh K, Shah A, Coviello AD, Herbst KL.

J Sex Med. 2014 Feb;11(2):563-73. doi: 10.1111/jsm.12368.

PMID:
24344872
6.

Dutasteride in men receiving testosterone therapy: a randomised, double-blind study.

Kacker R, Harisaran V, Given L, Miner M, Rittmaster R, Morgentaler A.

Andrologia. 2015 Mar;47(2):148-52. doi: 10.1111/and.12237.

PMID:
24499051
7.

5α-reductase type 1 modulates insulin sensitivity in men.

Upreti R, Hughes KA, Livingstone DE, Gray CD, Minns FC, Macfarlane DP, Marshall I, Stewart LH, Walker BR, Andrew R.

J Clin Endocrinol Metab. 2014 Aug;99(8):E1397-406. doi: 10.1210/jc.2014-1395.

8.

Musculoskeletal and prostate effects of combined testosterone and finasteride administration in older hypogonadal men: a randomized, controlled trial.

Borst SE, Yarrow JF, Conover CF, Nseyo U, Meuleman JR, Lipinska JA, Braith RW, Beck DT, Martin JS, Morrow M, Roessner S, Beggs LA, McCoy SC, Cannady DF 2nd, Shuster JJ.

Am J Physiol Endocrinol Metab. 2014 Feb 15;306(4):E433-42. doi: 10.1152/ajpendo.00592.2013.

9.

The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia.

Wurzel R, Ray P, Major-Walker K, Shannon J, Rittmaster R.

Prostate Cancer Prostatic Dis. 2007;10(2):149-54.

PMID:
17189955
10.

MK-386, an inhibitor of 5alpha-reductase type 1, reduces dihydrotestosterone concentrations in serum and sebum without affecting dihydrotestosterone concentrations in semen.

Schwartz JI, Tanaka WK, Wang DZ, Ebel DL, Geissler LA, Dallob A, Hafkin B, Gertz BJ.

J Clin Endocrinol Metab. 1997 May;82(5):1373-7.

PMID:
9141518
11.

The effect of 5alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men.

Amory JK, Wang C, Swerdloff RS, Anawalt BD, Matsumoto AM, Bremner WJ, Walker SE, Haberer LJ, Clark RV.

J Clin Endocrinol Metab. 2007 May;92(5):1659-65. Erratum in: J Clin Endocrinol Metab. 2007 Nov;92(11):4379.

PMID:
17299062
12.

Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle.

Bhasin S, Woodhouse L, Casaburi R, Singh AB, Mac RP, Lee M, Yarasheski KE, Sinha-Hikim I, Dzekov C, Dzekov J, Magliano L, Storer TW.

J Clin Endocrinol Metab. 2005 Feb;90(2):678-88.

PMID:
15562020
13.

Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor.

Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S.

J Clin Endocrinol Metab. 2004 May;89(5):2179-84.

PMID:
15126539
14.

Relationship among serum testosterone, sexual function, and response to treatment in men receiving dutasteride for benign prostatic hyperplasia.

Marberger M, Roehrborn CG, Marks LS, Wilson T, Rittmaster RS.

J Clin Endocrinol Metab. 2006 Apr;91(4):1323-8.

PMID:
16434455
15.

Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial.

Blackman MR, Sorkin JD, Münzer T, Bellantoni MF, Busby-Whitehead J, Stevens TE, Jayme J, O'Connor KG, Christmas C, Tobin JD, Stewart KJ, Cottrell E, St Clair C, Pabst KM, Harman SM.

JAMA. 2002 Nov 13;288(18):2282-92.

PMID:
12425705
16.

The effect of 5alpha-reductase inhibition with dutasteride and finasteride on bone mineral density, serum lipoproteins, hemoglobin, prostate specific antigen and sexual function in healthy young men.

Amory JK, Anawalt BD, Matsumoto AM, Page ST, Bremner WJ, Wang C, Swerdloff RS, Clark RV.

J Urol. 2008 Jun;179(6):2333-8. doi: 10.1016/j.juro.2008.01.145.

17.

The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer.

Tindall DJ, Rittmaster RS.

J Urol. 2008 Apr;179(4):1235-42. doi: 10.1016/j.juro.2007.11.033. Review. Erratum in: J Urol. 2008 Jun;179(6):2490.

18.

Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.

Bartsch G, Rittmaster RS, Klocker H.

Eur Urol. 2000 Apr;37(4):367-80. Review.

PMID:
10765065
19.

Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial.

Muller RL, Gerber L, Moreira DM, Andriole G, Castro-Santamaria R, Freedland SJ.

Eur Urol. 2012 Nov;62(5):757-64. doi: 10.1016/j.eururo.2012.05.025.

PMID:
22658758
20.

Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer.

Rittmaster R, Hahn RG, Ray P, Shannon JB, Wurzel R.

Urology. 2008 Oct;72(4):808-12. doi: 10.1016/j.urology.2008.06.032.

PMID:
18718641
Items per page

Supplemental Content

Support Center